$FOLD multi-bagger with multi-bottom recovery. $7.
Post# of 109
Posted On: 05/18/2016 6:11:25 PM
$FOLD multi-bagger with multi-bottom recovery. $7.07
called 6/18/14 $2.97
Website
Shares Outstanding: 127.05M
Float: 100.15M
% Held by Insiders: 4.04%
% Held by Institutions: 97.60%
Shares Short (as of Apr 29, 2016): 22.29M
Short Ratio (as of Apr 29, 2016): 8.07
Short % of Float (as of Apr 29, 2016): 29.11%
Shares Short (prior month): 24.67M
Headlines
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has completed Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; ATB200 that is in Phase II studies to treat pompe disease; AT2221, which is in Phase II studies for the treatment of pompe disease; and AT3375 to treat Parkinson's disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
called 6/18/14 $2.97
Website
Shares Outstanding: 127.05M
Float: 100.15M
% Held by Insiders: 4.04%
% Held by Institutions: 97.60%
Shares Short (as of Apr 29, 2016): 22.29M
Short Ratio (as of Apr 29, 2016): 8.07
Short % of Float (as of Apr 29, 2016): 29.11%
Shares Short (prior month): 24.67M
Headlines
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has completed Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; ATB200 that is in Phase II studies to treat pompe disease; AT2221, which is in Phase II studies for the treatment of pompe disease; and AT3375 to treat Parkinson's disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
(0)
(0)